Cargando…

IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis

Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Wueest, Stephan, Seelig, Eleonora, Timper, Katharina, Lyngbaek, Mark P., Karstoft, Kristian, Donath, Marc Y., Ellingsgaard, Helga, Konrad, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911215/
https://www.ncbi.nlm.nih.gov/pubmed/33572989
http://dx.doi.org/10.3390/metabo11020079
_version_ 1783656289024344064
author Wueest, Stephan
Seelig, Eleonora
Timper, Katharina
Lyngbaek, Mark P.
Karstoft, Kristian
Donath, Marc Y.
Ellingsgaard, Helga
Konrad, Daniel
author_facet Wueest, Stephan
Seelig, Eleonora
Timper, Katharina
Lyngbaek, Mark P.
Karstoft, Kristian
Donath, Marc Y.
Ellingsgaard, Helga
Konrad, Daniel
author_sort Wueest, Stephan
collection PubMed
description Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investigate whether IL-6 receptor blockade affects the levels of circulating adiponectin and leptin in obese human individuals. To this end, serum samples collected during a multicenter, double-blind clinical trial were analyzed. In the latter study, obese human subjects with or without type 2 diabetes were randomly assigned to recurrent placebo or intravenous tocilizumab (an IL-6 receptor antibody) administration during a 12-week exercise training intervention. Twelve weeks of tocilizumab administration (in combination with exercise training) trend wise enhanced the decrease in circulating leptin levels (−2.7 ± 8.2% in the placebo vs. −20.6 ± 5.6% in tocilizumab, p = 0.08) and significantly enhanced the increase in circulating adiponectin (3.4 ± 3.7% in the placebo vs. 27.0 ± 6.6% in tocilizumab, p = 0.01). In addition, circulating adiponectin levels were negatively correlated with the homeostatic model assessment of insulin resistance (HOMA-IR), indicating that increased adiponectin levels positively affect insulin sensitivity in people with obesity. In conclusion, IL-6 receptor blockade increases circulating adiponectin levels in people with obesity.
format Online
Article
Text
id pubmed-7911215
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79112152021-02-28 IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis Wueest, Stephan Seelig, Eleonora Timper, Katharina Lyngbaek, Mark P. Karstoft, Kristian Donath, Marc Y. Ellingsgaard, Helga Konrad, Daniel Metabolites Brief Report Human obesity is associated with decreased circulating adiponectin and elevated leptin levels. In vitro experiments and studies in high fat diet (HFD)-fed mice suggest that interleukin-6 (IL-6) may regulate adiponectin and leptin release from white adipose tissue (WAT). Herein, we aimed to investigate whether IL-6 receptor blockade affects the levels of circulating adiponectin and leptin in obese human individuals. To this end, serum samples collected during a multicenter, double-blind clinical trial were analyzed. In the latter study, obese human subjects with or without type 2 diabetes were randomly assigned to recurrent placebo or intravenous tocilizumab (an IL-6 receptor antibody) administration during a 12-week exercise training intervention. Twelve weeks of tocilizumab administration (in combination with exercise training) trend wise enhanced the decrease in circulating leptin levels (−2.7 ± 8.2% in the placebo vs. −20.6 ± 5.6% in tocilizumab, p = 0.08) and significantly enhanced the increase in circulating adiponectin (3.4 ± 3.7% in the placebo vs. 27.0 ± 6.6% in tocilizumab, p = 0.01). In addition, circulating adiponectin levels were negatively correlated with the homeostatic model assessment of insulin resistance (HOMA-IR), indicating that increased adiponectin levels positively affect insulin sensitivity in people with obesity. In conclusion, IL-6 receptor blockade increases circulating adiponectin levels in people with obesity. MDPI 2021-01-29 /pmc/articles/PMC7911215/ /pubmed/33572989 http://dx.doi.org/10.3390/metabo11020079 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Wueest, Stephan
Seelig, Eleonora
Timper, Katharina
Lyngbaek, Mark P.
Karstoft, Kristian
Donath, Marc Y.
Ellingsgaard, Helga
Konrad, Daniel
IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title_full IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title_fullStr IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title_full_unstemmed IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title_short IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
title_sort il-6 receptor blockade increases circulating adiponectin levels in people with obesity: an explanatory analysis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911215/
https://www.ncbi.nlm.nih.gov/pubmed/33572989
http://dx.doi.org/10.3390/metabo11020079
work_keys_str_mv AT wueeststephan il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT seeligeleonora il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT timperkatharina il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT lyngbaekmarkp il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT karstoftkristian il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT donathmarcy il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT ellingsgaardhelga il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis
AT konraddaniel il6receptorblockadeincreasescirculatingadiponectinlevelsinpeoplewithobesityanexplanatoryanalysis